Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8 T cell PET imaging with 89Zr-Df-crefmirlimab in giant cell arteritis and rheumatoid arthritis
2024-514489-38-01Phase 2Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label trial of 89Zr-crefmirlimab zodalpol in giant cell arteritis (GCA) and rheumatoid arthritis (RA) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Tracer uptake (SUV) in arteries and joints on 89Zr-Df-crefmirlimab PET/CT. Planned start Jul 2024; status: authorised.
02
Drugs
89Zr-crefmirlimab zodalpol
03
Conditions
giant cell arteritis (GCA)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-514489-38-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514489-38-01.